L. Straßl

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Bendamustine has demonstrated clinical activity and a favorable safety profile as monotherapy or in combination with rituximab in lymphoid malignancies. As interventional trials do not always reflect clinical reality, we were interested in the treatment modalities and the outcome of bendamustine-based first-line therapy in patients with advanced indolent(More)
  • 1